Terry Heiman-Patterson, MD, Director of the Temple MDA/ALS Center of Hope, offered insight to the Associated Press for an article about NurOwn, a stem cell-based therapy for patients with ALS, or amyotrophic lateral sclerosis. At the time, the treatment was awaiting approval by the U.S. Food and Drug Administration (FDA). The FDA eventually voted against the therapy.
Weather Alert: A major winter storm is likely to impact the Philadelphia region this weekend into Monday. Temple Health remains open, though some appointments or services may be adjusted. Patients will be contacted directly if their visit is affected. Please check TempleHealth.org for updates and monitor myTempleHealth for changes to scheduled appointments.
800-TEMPLE-MED
Schedule Appointment
SEARCH TEMPLE HEALTH